(Q37686353)

22 August 2017

1 reference

title

Targeting the bone microenvironment in multiple myeloma (English)

1 reference

22 August 2017

G David Roodman

1

1 reference

22 August 2017

language of work or name

1 reference

4 February 2010

1 reference

Journal of Bone and Mineral Metabolism

22 August 2017

published in

1 reference

22 August 2017

volume

28

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

244-250

1 reference

https://scigraph.springernature.com/pub.10.1007/s00774-009-0154-7

22 August 2017

exact match

0 references

cites work

Wnt signaling in osteoblasts and bone diseases

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00774-009-0154-7

Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00774-009-0154-7

Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts

21 January 2018

1 reference

12 December 2020

The SCID-hu myeloma model

1 reference

12 December 2020

Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma

1 reference

12 December 2020

Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance.

1 reference

12 December 2020

Myeloma bone disease and proteasome inhibition therapies.

1 reference

12 December 2020

Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model

1 reference

12 December 2020

Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma

1 reference

12 December 2020

Cytokines involved in the progression of multiple myeloma

1 reference

12 December 2020

A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK.

1 reference

12 December 2020

IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma

1 reference

12 December 2020

Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma

1 reference

12 December 2020

The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma

1 reference

12 December 2020

Signals that determine the fate of osteoblastic cells

1 reference

12 December 2020

A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.

1 reference

12 December 2020

Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma

1 reference

12 December 2020

An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma

1 reference

12 December 2020

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

1 reference

12 December 2020

1 reference

12 December 2020

Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma

1 reference

12 December 2020

Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades

1 reference

12 December 2020

New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).

1 reference

12 December 2020

Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.

1 reference

12 December 2020

Fracture risk with multiple myeloma: a population-based study

1 reference

12 December 2020

Activated beta-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction

1 reference

12 December 2020

Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment.

1 reference

12 December 2020

Myeloma cells (5TMM) and their interactions with the marrow microenvironment

1 reference

12 December 2020

The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients

1 reference

12 December 2020

Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma

1 reference

12 December 2020

Response patterns of purified myeloma cells to hematopoietic growth factors

1 reference

12 December 2020

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

1 reference

12 December 2020

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

1 reference

12 December 2020

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion

1 reference

12 December 2020

Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma

1 reference

12 December 2020

Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays

1 reference

12 December 2020

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

1 reference

12 December 2020

MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.

1 reference

12 December 2020

Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease

1 reference

12 December 2020

Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma.

1 reference

12 December 2020

Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation

1 reference

12 December 2020

IL-3 induces differentiation of bone marrow precursor cells to osteoclast-like cells.

1 reference

12 December 2020

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

1 reference

12 December 2020

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

1 reference

12 December 2020

Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis

1 reference

12 December 2020

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

1 reference

12 December 2020

Pathogenesis of myeloma bone disease

1 reference

12 December 2020

Immunocytochemistry reveals RANKL expression of myeloma cells

1 reference

12 December 2020

Bortezomib inhibits human osteoclastogenesis.

1 reference

12 December 2020

Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients

1 reference

12 December 2020

IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells

1 reference

12 December 2020

Clinical evaluation of onset of analgesia using intravenous pamidronate in metastatic bone pain

1 reference

12 December 2020

Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.

1 reference

12 December 2020

Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption

1 reference

12 December 2020

Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease

1 reference

12 December 2020

10.1007/S00774-009-0154-7

Identifiers

DOI

1 reference

22 August 2017

1 reference